Newsbenzinga
EyePoint Reports DURAVYU Non‑Inferior To Aflibercept In Ad Hoc Analysis; Primary BCVA Endpoint Not Met In Full Dataset
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…